2-[3,5-二(三氟甲基)苯基]-N,2-二甲基-N-[4-(2-甲基苯基)-6-吗啉-4-基-吡啶-3-基]丙酰胺

Befetupitant (Ro67-5930) is a drug developed by Hoffmann-La Roche which acts as a potent and selective antagonist for the NK1 receptor. It was originally developed as a potential antiemetic drug, though development was ultimately discontinued after a related drug netupitant was deemed to be more suitable for clinical development. Befetupitant has however continued to be researched for other possible applications such as treatment of corneal neovascularization.